Literature DB >> 28185029

Antiphospholipid antibodies proposed in the diagnosis of infective endocarditis.

C Zaratzian1, F Gouriet1, H Tissot-Dupont1, J-P Casalta1, M Million1, N Bardin2, D Grisoli3, G Habib4, D Raoult5.   

Abstract

Antiphospholipid antibodies (aPL) may occur alone or associated with other diseases. To evaluate aPL, tested as anticardiolipin antibodies (IgG aCL) in infective endocarditis (IE) diagnosis, we investigated their prevalence in a cohort of 651 patients with IE suspicion. aPL was significantly associated with definite IE versus IE-rejected patients. Their mean levels were significantly higher in patients with definite IE versus possible IE. When applied as Duke minor criterion, they were significantly more often positive, and at higher levels, in patients with definite IE than in patients with possible or rejected IE. aPL could be helpful in difficult cases of IE diagnosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28185029     DOI: 10.1007/s10096-017-2903-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

1.  Guidelines on the investigation and management of the antiphospholipid syndrome.

Authors:  M Greaves; H Cohen; S J MacHin; I Mackie
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

2.  Contribution of systematic serological testing in diagnosis of infective endocarditis.

Authors:  D Raoult; J P Casalta; H Richet; M Khan; E Bernit; C Rovery; S Branger; F Gouriet; G Imbert; E Bothello; F Collart; G Habib
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome.

Authors:  Aleksandra Djokovic; Ljudmila Stojanovich; Milica Kontic; Natasa Stanisavljevic; Slavica Radovanovic; Dragomir Marisavljevic
Journal:  Isr Med Assoc J       Date:  2014-03       Impact factor: 0.892

Review 4.  The pathogenesis of the antiphospholipid syndrome.

Authors:  Bill Giannakopoulos; Steven A Krilis
Journal:  N Engl J Med       Date:  2013-03-14       Impact factor: 91.245

5.  Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy.

Authors:  D Verrot; M San-Marco; C Dravet; P Genton; P Disdier; G Bolla; J R Harle; L Reynaud; P J Weiller
Journal:  Am J Med       Date:  1997-07       Impact factor: 4.965

6.  The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events.

Authors:  L I Kupferwasser; G Hafner; S Mohr-Kahaly; R Erbel; J Meyer; H Darius
Journal:  J Am Coll Cardiol       Date:  1999-04       Impact factor: 24.094

7.  Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies.

Authors:  S Zuily; V Regnault; C Selton-Suty; V Eschwège; J-F Bruntz; E Bode-Dotto; E De Maistre; P Dotto; C Perret-Guillaume; T Lecompte; D Wahl
Journal:  Circulation       Date:  2011-06-20       Impact factor: 29.690

8.  Antiphospholipid antibody-associated non-infective mitral valve endocarditis successfully treated with medical therapy.

Authors:  Tahmeed Contractor; Adrian Bell; Atul Khasnis; Bruce J Silverberg; Matthew W Martinez
Journal:  J Heart Valve Dis       Date:  2013-01

Review 9.  Antiphospholipid syndrome; its implication in cardiovascular diseases: a review.

Authors:  Ioanna Koniari; Stavros N Siminelakis; Nikolaos G Baikoussis; Georgios Papadopoulos; John Goudevenos; Efstratios Apostolakis
Journal:  J Cardiothorac Surg       Date:  2010-11-03       Impact factor: 1.637

Review 10.  Infective endocarditis with antineutrophil cytoplasmic antibody: report of 13 cases and literature review.

Authors:  Chun-Mei Ying; Dong-Ting Yao; Hui-Hua Ding; Cheng-De Yang
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.